Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The main objective of this clinical trial in randomizing HIV infected patients under good HIV
control with tenofovir (TDF), emtricitabine (or lamivudine) plus lopinavir/ritonavir (LPV/r)
into switching the regimen to raltegravir (RAL) with darunavir/ritonavir (DRV/r) or
continuing the ongoing regimen to compare these two groups' estimated glomerular filtration
rate (eGFR) is to investigate whether anti-HIV treatment that does not contain TDF or other
reverse-transcriptase inhibitors (NTRI sparing regimen) can be protective of patients' renal
functions and has the same virological efficacy in comparison with a standard treatment with
TDF, or not.
Phase:
N/A
Details
Lead Sponsor:
National Center for Global Health and Medicine, Japan